1 citations
,
October 2018 in “InTech eBooks” Ethosomes are a promising method for treating hair loss by delivering drugs directly to the scalp.
1 citations
,
July 2025 in “MedComm – Biomaterials and Applications” Microneedles show promise for cancer diagnosis and treatment due to their minimally invasive nature and effective drug delivery.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
20 citations
,
August 2020 in “Stem Cell Research & Therapy” miR-150 helps blood vessel cells develop and speeds up blood clot healing.
44 citations
,
September 2020 in “International Journal of Molecular Sciences” New treatments are needed for PCOS that target its genetic, hormonal, and metabolic causes.
February 2026 in “Preprints.org” New therapies and personalized approaches improve wound healing and patient quality of life.
2 citations
,
March 2025 in “Cancer Gene Therapy” Targeting Sirt1 can reduce androgen levels and slow glioblastoma growth.
July 2024 in “Reactions Weekly”
17 citations
,
May 2023 in “Aesthetic Plastic Surgery” Stem cell therapies show the most promise for anti-aging benefits.
5 citations
,
April 2016 in “PubMed” Cetuximab often causes skin problems, but they can be managed without stopping treatment.
July 2026 in “Quality in Sport” New treatments for alopecia areata focus on targeted drugs and regenerative therapies, but challenges remain.
June 2021 in “bioRxiv (Cold Spring Harbor Laboratory)” Gene therapy in mice increased lifespan and improved health without causing cancer.
28 citations
,
December 2006 in “Clinical lung cancer” Early recognition and management of skin side effects from new cancer therapies can prevent treatment delays.
5 citations
,
October 2022 in “BMC genomics” Certain microRNAs are important for sheep hair follicle development and could help improve wool quality.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
June 2026 in “Strathprints: The University of Strathclyde institutional repository (University of Strathclyde)” Topical IKKα inhibitors may help prevent CCS tumours.
19 citations
,
September 2015 in “Therapeutic Delivery” Active transdermal technologies in cosmetics help deliver skin treatments effectively, but their safety and effectiveness depend on skin type and treatment choice.
July 2026 in “The Bioscan.” Drug repurposing speeds up drug development and addresses unmet medical needs.
September 2005 in “電子情報通信学会ソサイエティ大会講演論文集” Cancer prevention has advanced significantly, with some strategies proving successful.
8 citations
,
June 2004 in “Journal of Investigative Dermatology” Certain peptides can prevent hair loss in young rats caused by a cancer drug.
August 2019 in “Stem cells” New treatments for hair loss, fertility, and wound healing are being explored.
June 2025 in “International Journal of Molecular Sciences” Targeting EMT and fibrotic remodeling may help treat androgenetic alopecia.
May 2026 in “Bioorganic Chemistry” The combination of high-dose toremifene and capecitabine was effective for advanced recurrent breast cancer.
September 2025 in “Blood Advances” Targeting androgen receptor signaling may improve acute myeloid leukemia treatment.
May 2025 in “Orphanet Journal of Rare Diseases” TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
508 citations
,
June 2009 in “Current drug metabolism” Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.
7 citations
,
March 2024 in “Non-coding RNA Research” DNA methylation of miR-365-1 causes hair follicle stem cell death by affecting DAP3.
8 citations
,
March 2023 in “International Wound Journal” IGF2BP3 and other m6A-related genes are linked to keloid formation and could be potential treatment targets.
May 2026 in “Zenodo (CERN European Organization for Nuclear Research)” ONCO-NK-TRANSITION-GM1 is a low-cost, effective cancer treatment with a high cure rate and no severe side effects.